Cytosorbents (CTSO) Projected to Post Earnings on Thursday

Cytosorbents (NASDAQ:CTSO) is expected to be posting its Q3 2025 results after the market closes on Thursday, November 13th. Analysts expect Cytosorbents to post earnings of ($0.06) per share and revenue of $10.0190 million for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:30 PM ET.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Friday, January 3rd. The medical research company reported ($0.08) earnings per share (EPS) for the quarter. Cytosorbents had a negative net margin of 25.58% and a negative return on equity of 111.97%. The firm had revenue of $8.61 million for the quarter. On average, analysts expect Cytosorbents to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytosorbents Stock Performance

Shares of CTSO opened at $0.72 on Tuesday. The stock has a market capitalization of $45.29 million, a PE ratio of -4.24 and a beta of 1.28. The business’s fifty day moving average price is $0.90 and its 200 day moving average price is $0.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 2.34 and a quick ratio of 1.96. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.61.

Hedge Funds Weigh In On Cytosorbents

An institutional investor recently raised its position in Cytosorbents stock. Goldman Sachs Group Inc. raised its stake in shares of Cytosorbents Corporation (NASDAQ:CTSO) by 149.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,662 shares of the medical research company’s stock after buying an additional 37,519 shares during the period. Goldman Sachs Group Inc. owned approximately 0.10% of Cytosorbents worth $63,000 as of its most recent SEC filing. 32.87% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. D. Boral Capital reissued a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a report on Tuesday, September 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a research report on Tuesday, October 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $5.50.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.